Evommune, Inc. (EVMN) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 12, 2026, Evommune, Inc. (EVMN) trades at a price-to-earnings ratio of -9.5x, with a stock price of $20.69 and trailing twelve-month earnings per share of $-2.18.
Relative to the broader market, EVMN trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our EVMN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
EVMN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
EVMN P/E vs Peers
Closest public peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $64B | 14.7Lowest | 2.33 | +8% | |
| $398B | 94.8 | - | -1% | |
| $1.1T | 50.6 | 1.76Best | +96%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
What if you invested $1,000 in EVMN back in 2026?
Total return with dividends reinvested · 0+ years of data
Calculate ReturnsHow much would $100/month in EVMN be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs EVMN Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationHow does EVMN stack up against peers?
Compare business quality, growth, and profitability against top sector peers.
Compare NowEVMN — Frequently Asked Questions
Quick answers to the most common questions about buying EVMN stock.
What is EVMN's P/E ratio?
Evommune, Inc. (EVMN) trailing twelve-month P/E ratio is -9.5x, based on TTM diluted EPS of $-2.18. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is EVMN stock overvalued or undervalued?
EVMN current P/E: -9.5x. 5-year average P/E: N/A. Percentile: N/A.
Is EVMN stock expensive?
EVMN is fairly valued relative to its own history. The current P/E of -9.5x is near the 5-year average of N/A (N/A percentile of historical range).
What is EVMN's historical P/E range?
Over the past 5 years, EVMN's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -9.5x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does EVMN's P/E compare to the S&P 500?
EVMN trades at -9.5x P/E versus the S&P 500 median of 24.9x. The 138% discount to the market suggests lower growth expectations or perceived higher risk.
How does EVMN's valuation compare to sector peers?
Evommune, Inc. P/E of -9.5x can be benchmarked against sector peers in the comparison table on this page.
What is EVMN's PEG ratio?
EVMN PEG ratio is N/A, based on a P/E of -9.5x and EPS growth of 4.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is EVMN's earnings yield?
EVMN earnings yield is N/A, the inverse of its -9.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.